AdjuTec Pharma AS

APC148 is Phase 1 Ready – Successful Completion of the Toxicology Program

Oslo, Norway, 10 March, 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company is happy to announce the successful completion of the preclinical toxicology program for our lead product APC148. The program has been performed in collaboration with Evotec at different European facilities. The results clearly define a safe dose for the initiation of the phase 1 program.

Manufacturing of drug substance and drug product have been contracted to European manufacturers, securing a robust a supply chain.

Adjutec has scheduled a meeting with the Swedish medicinal agency before summer to seek advice on the phase 1 protocol. The phase 1 program will start with the recruitment of approximately 80 healthy volunteers at a clinical unit in Uppsala, Sweden. The clinical program will define a safe and effective dose of APC148 and the companion antibiotic. This dose will be verified treating patients in the phase 2/3 program.
"Adjutec raised NOK 52mill in private and public funding in 2021 to execute on the APC148 preclinical program needed for a clinical trial application. Our outstanding team is now delivering on these milestones. Despite Covid19 and logistical challenges, APC148 is still on-track to recruit the first subjects to our phase 1 program in 2023. We’re so exited to get started and to contribute to the clinical pipeline of new innovations in antimicrobial resistance", comments CEO Bjørn Klem.
About antimicrobial resistance (AMR) –

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit

Please contact:

Follow us on LinkedIn and Twitter